A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.
about
Targeting angiogenesis in gynecologic cancersPharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerationsEGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy.Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma.Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer.Locking Src/Abl Tyrosine Kinase Activities Regulate Cell Differentiation and Invasion of Human Cervical Cancer Cells Expressing E6/E7 Oncoproteins of High-Risk HPVSmall intestine metastasis from cervical cancer with acute abdomen: A case reportNew molecular targets against cervical cancer.TACC3 is essential for EGF-mediated EMT in cervical cancerCytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines.Patient age, tumor appearance and tumor size are risk factors for early recurrence of cervical cancer.Therapeutic advances in women's cancersInhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16A novel radioresistant mechanism of galectin-1 mediated by H-Ras-dependent pathways in cervical cancer cells.Prognostic Impact of Epidermal Growth Factor Receptor Overexpression in Patients with Cervical Cancer: A Meta-Analysis.A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer.Treatment options in recurrent cervical cancer (Review).Chemotherapy and molecular targeting therapy for recurrent cervical cancerRequirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer.Nonsurgical management of cervical cancer: locally advanced, recurrent, and metastatic disease, survivorship, and beyond.A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group StudyEmerging biological treatments for uterine cervical carcinoma.Erlotinib in a patient with vaginal carcinoma and pulmonary metastasis: A case report.EGFR protein expression and gene amplification in squamous intraepithelial lesions and squamous cell carcinomas of the cervix.Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.Pharmacotherapy of cervical cancer.Epidermal growth factor receptor as a biomarker for cervical cancer.Emerging drugs for cervical cancer.Management of advanced or recurrent cervical cancer: chemotherapy and beyond.Updates in systemic treatment for metastatic cervical cancer.Emerging drugs for the treatment of cervical cancer.Signaling pathways in HPV-associated cancers and therapeutic implications.Immunotherapy and targeted therapy for cervical cancer: an update.Mutation analysis of EGFR and its correlation with the HPV in Indian cervical cancer patients.MicroRNA-221 targets PTEN to reduce the sensitivity of cervical cancer cells to gefitinib through the PI3K/Akt signaling pathway.Investigational drugs for the treatment of cervical cancer.In vitro evaluation of the effects of gefitinib on the cytotoxic activity of selected anticancer agents in a panel of human endometrial cancer cell lines.Intensity-modulated radiotherapy combined with iodine-125 seed implantation in non-central recurrence of cervical cancer: A case report and literature review.Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells.Icotinib hydrochloride enhances chemo- and radiosensitivity by inhibiting EGFR signaling and attenuating RAD51 expression and function in Hela S3 cells.
P2860
Q26824766-240CA329-2FA6-4FFD-B0AD-10A0671A4332Q28086919-87045FBF-BB1B-4C80-A25E-09E92ABDF1CAQ33359764-A5D9A978-9D30-4C0B-B986-205B54137B41Q33475963-61B54332-DC94-440C-9046-19710BE7EFB3Q33917356-30AE68E4-4888-4D4F-AD4B-BE65BA09D79EQ34123748-E79894B9-C23D-452B-A35E-07BFDB32D4E3Q34582539-76F692B7-2923-40C3-B3DE-6268CF71A3C4Q34700859-E70C0378-F214-421E-82B1-2B1343FD760CQ34925509-7B8BF7F1-A96E-4C67-B93E-4190E70566BAQ35067562-65DC4394-F8C0-44EB-848E-DFA5F0FA4D91Q35180066-3D370374-6B6D-45B7-98CF-0D929701E600Q35418973-5F3D9D2B-F9EF-47CE-9615-DB0B2CC24000Q35528877-07A54C5D-6A41-4048-B484-1F54B98A7CB0Q35723822-E537C79F-43FF-499C-A88F-399E34623F2CQ36082772-DCE9F4FF-3D48-4CB9-8AE9-5903394B35A5Q36214463-6D7994A4-F485-4A80-AED0-FD426A9353EDQ36216582-D5A241D3-37A1-4438-BA25-CD7DFEA758D9Q36897266-2D95555A-5977-420E-B242-2C4E2FC69978Q37000743-3E2B936C-9F73-4426-99D1-40511C0F7407Q37036792-458E2440-129C-4C72-9905-4DB6C9C9EC4AQ37294922-4346433E-93B9-42E5-93F4-146DB1B519FBQ37540968-E6685A64-6AAE-43F8-8E2E-09B27EEFB509Q37574936-1527563B-C821-4300-93AF-1B196420006BQ37587410-57A4E5F2-2082-47C1-90B5-75CA8836B78AQ37671783-A41C2573-C0A4-4524-A19B-0C37E6521F15Q37773995-B3DE4F49-21C7-4107-BCCD-E3AB4EF4B885Q37843137-0FD65D8B-4DAF-4D71-9498-80233F90204AQ38005222-54CD7DE1-801C-4181-87B8-FAC1D5501DA6Q38178742-AE1C22F3-E8E2-4AE3-9C1C-D5E5AA5FB1D2Q38178824-1E481825-15E3-41B1-9274-B408664F01C2Q38314157-9F32C523-8A53-40DA-B98A-248EF2CD49B2Q38370778-BFC2DF84-ABBF-4874-B841-F1531D27D1F1Q38633525-79843186-3C22-45AE-8AA3-605F3D8EEDDFQ38804094-2A50CE01-518C-4FF4-B244-EF22E12A62E9Q38826622-5E995591-6C35-45EB-AC4B-04BC7693668CQ39168925-572B6044-3EDF-43BA-990E-1644205D65BFQ39946514-5C851B53-D13B-400F-8851-E0FD58146058Q41676879-074AC369-DD3F-46A9-8044-E4E1F70D38BFQ47754114-A2FFE756-7CE7-4675-A37B-CDA3F22BC61CQ52725887-801A3323-C8B2-4061-AD24-6F4ED9C94BB9
P2860
A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
A phase II trial to evaluate g ...... or metastatic cervical cancer.
@en
A phase II trial to evaluate g ...... or metastatic cervical cancer.
@nl
type
label
A phase II trial to evaluate g ...... or metastatic cervical cancer.
@en
A phase II trial to evaluate g ...... or metastatic cervical cancer.
@nl
prefLabel
A phase II trial to evaluate g ...... or metastatic cervical cancer.
@en
A phase II trial to evaluate g ...... or metastatic cervical cancer.
@nl
P2093
P1433
P1476
A phase II trial to evaluate g ...... or metastatic cervical cancer.
@en
P2093
A Goncalves
A Tisseron Carrasco
L Chaigneau
L Gladieff
P356
10.1016/J.YGYNO.2007.07.057
P407
P577
2007-11-05T00:00:00Z